KR20240148001A - 자가면역 질환의 치료를 위한 인터류킨-2 뮤테인 - Google Patents

자가면역 질환의 치료를 위한 인터류킨-2 뮤테인 Download PDF

Info

Publication number
KR20240148001A
KR20240148001A KR1020247030225A KR20247030225A KR20240148001A KR 20240148001 A KR20240148001 A KR 20240148001A KR 1020247030225 A KR1020247030225 A KR 1020247030225A KR 20247030225 A KR20247030225 A KR 20247030225A KR 20240148001 A KR20240148001 A KR 20240148001A
Authority
KR
South Korea
Prior art keywords
fold
amino acid
seq
variant
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247030225A
Other languages
English (en)
Korean (ko)
Inventor
아셔 샤히터
모히트 마투르
데이비드 윌리엄 올다흐
수잔 슬론
질 야브로우
니콜 아크라모프
다이앤 마
윌리엄 씨 터브스
미카엘라 슐츠
Original Assignee
비스테라, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비스테라, 인크. filed Critical 비스테라, 인크.
Publication of KR20240148001A publication Critical patent/KR20240148001A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020247030225A 2022-02-11 2023-02-10 자가면역 질환의 치료를 위한 인터류킨-2 뮤테인 Pending KR20240148001A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263309293P 2022-02-11 2022-02-11
US63/309,293 2022-02-11
PCT/US2023/062395 WO2023154870A1 (en) 2022-02-11 2023-02-10 Interleukin-2 muteins for the treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
KR20240148001A true KR20240148001A (ko) 2024-10-10

Family

ID=85476118

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247030225A Pending KR20240148001A (ko) 2022-02-11 2023-02-10 자가면역 질환의 치료를 위한 인터류킨-2 뮤테인

Country Status (10)

Country Link
US (1) US20230390360A1 (https=)
EP (1) EP4475875A1 (https=)
JP (1) JP2025506173A (https=)
KR (1) KR20240148001A (https=)
CN (2) CN119013034A (https=)
AU (1) AU2023219773A1 (https=)
CA (1) CA3243493A1 (https=)
MX (1) MX2024009868A (https=)
TW (1) TW202400218A (https=)
WO (1) WO2023154870A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
US12098178B2 (en) 2020-12-04 2024-09-24 Visterra, Inc. Methods of using interleukin-2 agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170510A (es) * 2015-04-10 2018-02-26 Amgen Inc Muteínas de interuquina 2 para la expansión de células t regulatorias
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
HRP20260151T1 (hr) 2016-08-02 2026-03-27 Visterra, Inc. Modificirani polipeptidi i njihova uporaba
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof

Also Published As

Publication number Publication date
CN120346304A (zh) 2025-07-22
AU2023219773A1 (en) 2024-08-01
US20230390360A1 (en) 2023-12-07
WO2023154870A1 (en) 2023-08-17
MX2024009868A (es) 2024-08-20
CA3243493A1 (en) 2023-08-17
JP2025506173A (ja) 2025-03-07
TW202400218A (zh) 2024-01-01
EP4475875A1 (en) 2024-12-18
CN119013034A (zh) 2024-11-22

Similar Documents

Publication Publication Date Title
US20250059249A1 (en) Interleukin-2 agents and uses thereof
ES2777778T3 (es) Variantes de CTLA-4
JP2022507606A (ja) Ｉｌ－７タンパク質と免疫チェックポイント阻害剤の組み合わせで腫瘍を治療する方法
JP7678802B2 (ja) Ｓｉｇｌｅｃ－９ＥＣＤ融合分子及びその使用方法
US20220226442A1 (en) Interleukin-2 agents and uses thereof
US12098178B2 (en) Methods of using interleukin-2 agents
CN114302736A (zh) 变体icos配体(icosl)融合蛋白的方法和用途
KR20240148001A (ko) 자가면역 질환의 치료를 위한 인터류킨-2 뮤테인
JP2022033047A (ja) 血液脳関門を越える送達のための併用療法
HK40124714A (zh) 用於治疗自身免疫性疾病的白细胞介素-2突变蛋白
HK40113125A (zh) 用於治疗自身免疫性疾病的白细胞介素-2突变蛋白
EA049020B1 (ru) Средства на основе интерлейкина-2 и их применение

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000